Swiss drugmaker Roche said on Monday it is evaluating options for its lung disease drug Esbriet, which has seen declining sales due to competition from cheaper copycat versions. Generic versions of Esbriet began entering the market in the second quarter of 2022, impacting sales of Roche's drug. Sales of Esbriet fell 70% to 202 million Swiss francs ($229.42 million) in 2023.
(Bloomberg) -- Roche Holding AG is considering selling Esbriet, a lung disease drug that’s seen sales plummet amid competition from cheaper generics.Most Read from BloombergBYD’s New $233,450 EV Supercar to Rival Ferrari, LamborghiniStock Rally Stalls at Start of Data-Packed Week: Markets WrapFreddie Mercury’s London Residence Lists at £30 MillionJacob Rothschild, Financier and Philanthropist, Dies at 87Poland’s Famously Frank Top Diplomat Lands a Blow With Rebuff of RussiaThe Swiss pharmaceutic
Xolair, a 20-year-old asthma drug sold by Roche and Novartis, significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting. Based on the results, presented at the American Academy of Allergy, Asthma & Immunology meeting in Washington, the U.S. Food and Drug Administration approved the drug earlier this month for adults and children age 1 year or older for reducing allergic reactions that may occur from accidental exposure.